ArticleFrontiers in public health2025
A retrospective study of the clinical diagnosis and treatment of 158 cases of COVID-19.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to summarize the clinical characteristics, management, and outcomes, and to identify independent risk factors associated with the severity in a cohort of coronavirus disease 2019 (COVID-19) patients from early-pandemic Fujian Province, China. Methods: A total of 158 patients with confirmed COVID-19 were recruited from 10 designed hospitals of the Fujian province between January 22 and February 26, 2020. Their clinical, laboratory, computed tomography imaging, treatment, and outcome data were collected and summarized from electronic medical records. Potential independent risk factors associated with COVID-19 severity were explored by binary logistic multivariate regression. Results: Of the 158 COVID-19 patients, 36 had mild, 106 had moderate, 8 had severe, and 8 had critical disease severity. The median age was 45 years (interquartile range 35-55) and 81 (51.3%) were men. 8.2% had a history of smoking. 31.6% had chronic underlying conditions, among which hypertension (13.9%), diabetes (7.6%), and liver disease (7.0%) were the most common. The most common initial symptom was fever, followed by cough, sputum expectoration, and muscle soreness. 94.3% of patients had abnormal imaging findings on chest computed tomography or X-ray. Patients with severe/critical disease had significantly more prominent laboratory abnormalities, including an abnormal lymphocyte count and abnormal levels of white blood cells, albumin, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, and D-dimer than mild/moderate patients (all Conclusion: COVID-19 patients from Fujian province during early pandemic presented mostly as mild/moderate cases with fever and cough as the initial symptoms. The detection of cellular immune function, coagulation function, myocardial damage, and liver function can help assess the severity of COVID-19. Specifically, the most important risk factors were older age, WBC elevation, and D-dimer elevation. Timely comprehensive treatment might be beneficial in controlling COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.